Clinical Characteristics and Prothrombin Activity Levels of the Propositus and His Family Members
| . | Homozygous FVL + FII (n = 1) . | Heterozygous FVL + FII (n = 4) . | Heterozygous FII (n = 4) . | Noncarriers (n = 3) . |
|---|---|---|---|---|
| Pedigree code | II.9 | I.1, II.4, III.3, III.5 | II.2, II.8, III.1, III.6 | II.1, III.2, III.4 |
| Men/women | 0/1 | 1/3 | 2/2 | 0/3 |
| Age, yr | 34 | 67, 43, 24, 18 | 44, 38, 22, 14 | 45, 19, 19 |
| Thrombotic episodes | ||||
| VTE, n | 1 | 0 | 0 | 0 |
| Myocardial infarction, n | 0 | 1 | 0 | 0 |
| Fetal loss, n | — | 0 | 0 | 1 |
| Exposure to environmental risk factors for VTE | ||||
| Episodes of surgery, trauma, or immobilization, n | 0 | 18 | 3 | 7 |
| Pregnancies, n | — | 10 | 2 | 6 |
| Use of oral contraceptives, yr | — | 18 | 2 | 11 |
| Prothrombin activity (%) | 160 | 134, 143, 106, 114 | 134, 124, 154, 122 | 99, 93,* 118* |
| . | Homozygous FVL + FII (n = 1) . | Heterozygous FVL + FII (n = 4) . | Heterozygous FII (n = 4) . | Noncarriers (n = 3) . |
|---|---|---|---|---|
| Pedigree code | II.9 | I.1, II.4, III.3, III.5 | II.2, II.8, III.1, III.6 | II.1, III.2, III.4 |
| Men/women | 0/1 | 1/3 | 2/2 | 0/3 |
| Age, yr | 34 | 67, 43, 24, 18 | 44, 38, 22, 14 | 45, 19, 19 |
| Thrombotic episodes | ||||
| VTE, n | 1 | 0 | 0 | 0 |
| Myocardial infarction, n | 0 | 1 | 0 | 0 |
| Fetal loss, n | — | 0 | 0 | 1 |
| Exposure to environmental risk factors for VTE | ||||
| Episodes of surgery, trauma, or immobilization, n | 0 | 18 | 3 | 7 |
| Pregnancies, n | — | 10 | 2 | 6 |
| Use of oral contraceptives, yr | — | 18 | 2 | 11 |
| Prothrombin activity (%) | 160 | 134, 143, 106, 114 | 134, 124, 154, 122 | 99, 93,* 118* |
Abbreviations: FVL, factor V Leiden; FII, prothrombin G20210A gene mutation; VTE, venous thromboembolism.
Measurement during use of oral contraceptives.